Italia markets open in 3 hours 51 minutes

Nanobiotix SA (0QAV.IL)

IOB - IOB Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
6,35-0,03 (-0,51%)
Alla chiusura: 10:25AM GMT
Schermo intero
Chiusura precedente6,38
Denaro0,00 x 0
Lettera0,00 x 0
Min-Max giorno6,35 - 6,35
Intervallo di 52 settimane6,35 - 10,35
Media Volume0
Beta (5 anni mensile)N/D
Rapporto PE (ttm)N/D
EPS (ttm)N/D
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Nanobiotix to Provide Operational Update and Report Full Year 2022 Financial Results on March 28, 2023

    Conference Call and Webcast to be Held at 2:00 P.M CET/8:00 A.M. EDT on March 29, 2023 PARIS and CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announces that it will provide an operational update and report its financial results for full-year ending December 31, 2022, on Tuesday, Mar

  • GlobeNewswire

    Voting Rights and Shares Capital of the Company

    In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)PARIS, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: DateNumber of SharesOutstandingTotal number of voting rightsTotal voting rights,theoretical1Total voting rights,exercisable2Ja

  • GlobeNewswire

    NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer

    Patients randomized in all planned major regions for pivotal phase 3 NANORAY-312 study with the United States added to Europe and AsiaNANORAY-312 now has sites activated across 80 sites globallyPhase 3 futility analysis expected in 2H 2023, with interim Phase 3 data expected in 2H 2024 PARIS and CAMBRIDGE, Mass., Dec. 27, 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expa